SEONGNAM, South Korea, April 6, 2025 /PRNewswire/ -- ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative ...

(RTTNews) - ABL Bio Inc. announced a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL Bio's blood-brain barrier or BBB shuttle ...

INCHEON, South Korea, ROCKVILLE, Md. and LONDON , Dec. 21, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing ...

Bristol Myers Squibb, GSK and Merck are contributing drug ingredients as part of their deals with the White House but are ...

The deal is the first for new CEO Luke Miels as the British drugmaker looks to overcome pressure on its HIV and vaccines ...

British Big Pharma GSK is welcoming President Donald Trump to the U.K. with a hefty gift: a five-year, $30 billion planned investment in U.S. R&D and manufacturing. The funds are set to be spread ...

Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply network Additional investments planned to expand the site's capacity (currently at 60,000 ...